Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Launched by IPSEN · Jan 9, 2017
Trial Information
Current as of June 03, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Men and women must be 18 years of age or older
- • A current diagnosis of advanced, unresectable GEP-NET
- • Provided written informed consent to participate in the study
- • Currently receiving lanreotide or octreotide LAR and has received at least one prior injection of current somatostatin analogues (SSA).
- Exclusion Criteria:
- • Receiving treatment with lanreotide or octreotide LAR as part of a clinical trial
- • Scheduled to receive a dose of lanreotide or octreotide LAR that would necessitate more than 1 injection on the same day
- • Scheduled to receive any other treatment in the infusion center/room on the same day and as part of the same appointment
- • Known hypersensitivity to somatostatin analogues
About Ipsen
Ipsen is a global biopharmaceutical group dedicated to innovation and specialty care, focusing on the discovery, development, and commercialization of transformative medicines for patients with serious diseases. With a strong emphasis on oncology, neuroscience, and rare diseases, Ipsen leverages cutting-edge research and advanced technologies to deliver high-quality therapies that address unmet medical needs. Committed to scientific excellence and ethical practices, Ipsen collaborates with healthcare professionals and stakeholders to drive patient-centered solutions and improve health outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Charlotte, North Carolina, United States
Kenner, Louisiana, United States
Tucson, Arizona, United States
East Setauket, New York, United States
Patients applied
Trial Officials
Ipsen Medical Director
Study Director
Ipsen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials